Stock Events

Stock Events

NanoViricides 

€0.96
55
-€0.03-3.03% Today

Statistics

Day High
0.96
Day Low
0.96
52W High
1.63
52W Low
0.64
Volume
0
Avg. Volume
-
Mkt Cap
20.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.2
-0.16
-0.12
-0.08
Expected EPS
-0.08
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-16.62MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NV3P.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences is a biopharmaceutical company that develops antiviral drugs, directly competing with NanoViricides' focus on developing novel treatments for viral diseases.
Moderna
MRNA
Mkt Cap20.12B
Moderna is known for its mRNA technology used in vaccines, including for viruses, positioning it as a competitor in the viral treatment space.
BioNTech
BNTX
Mkt Cap26.67B
BioNTech, similar to Moderna, works on mRNA-based vaccines and therapies for infectious diseases, competing in the viral treatment market.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals develops antiviral drugs and treatments, including monoclonal antibodies, which are in direct competition with NanoViricides' antiviral therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals engages in the creation of antiviral drugs among other therapies, making it a competitor in the viral disease treatment sector.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie has a portfolio that includes antiviral drugs for diseases like HIV and hepatitis, competing with NanoViricides in the antiviral space.
Pfizer
PFE
Mkt Cap153.59B
Pfizer develops and markets drugs and vaccines for a wide range of infectious diseases, including viral infections, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for viral infections, competing in the same space as NanoViricides.
Novavax
NVAX
Mkt Cap1.34B
Novavax focuses on developing vaccines for infectious diseases, including viral infections, positioning it as a competitor in the prevention and treatment of viral diseases.
Sarepta Therapeutics
SRPT
Mkt Cap2.13B
Sarepta Therapeutics, while primarily focused on genetic medicine, also explores treatments for infectious diseases, potentially competing in the viral therapy market.

About

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Show more...
CEO
Dr. Anil R. Diwan Ph.D.
Employees
7
Country
United States
ISIN
US6300873022
WKN
000A2PSNF

Listings

STU
DE
NV3P.STU
MU
DE
NV3P.MU
F
DE
NV3P.F
XASE
US
NNVC

0 Comments

Share your thoughts

FAQ

What is NanoViricides stock price today?▼
The current price of NV3P.F is €0.96 EUR — it has decreased by -3.03% in the past 24 hours. Watch NanoViricides stock price performance more closely on the chart.
What is NanoViricides stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NanoViricides stocks are traded under the ticker NV3P.F.
Is NanoViricides stock price growing?▼
NV3P.F stock has fallen by -4% compared to the previous week, the month change is a +28.86% rise, over the last year NanoViricides has showed a -12.73% decrease.
What is NanoViricides market cap?▼
Today NanoViricides has the market capitalization of 20.73M
When is the next NanoViricides earnings date?▼
NanoViricides is going to release the next earnings report on May 19, 2026.
What is NanoViricides revenue for the last year?▼
NanoViricides revenue for the last year amounts to 0 EUR.
What is NanoViricides net income for the last year?▼
NV3P.F net income for the last year is -16.62M EUR.
How many employees does NanoViricides have?▼
As of April 29, 2026, the company has 7 employees.
In which sector is NanoViricides located?▼
NanoViricides operates in the Health & Wellness sector.
When did NanoViricides complete a stock split?▼
NanoViricides has not had any recent stock splits.
Where is NanoViricides headquartered?▼
NanoViricides is headquartered in Shelton, United States.